SDL Sdl Plc

    
  SDL PLC
  09 October 2008
   


    SDL Translation Management software selected by Genzyme Europe

    Maidenhead, UK - 9th October 2008 - SDL, the leading provider of Global Information Management (GIM) solutions, announced today that
Genzyme Europe (Genzyme) has selected a Global Information Management system from SDL that meets the new Regulatory Translation Management
requirements in Europe, particularly the new XML-based Product Information Management (PIM) standard for the European Medicines Agency
(EMEA) centralized procedure. 

    The SDL Global Information Management system was selected by Genzyme to help them simplify regulatory processes through the deployment
of a central translation management solution. The SDL system has the ability to support and enhance the process of creating multilingual
content compliant with the upcoming EMEA XML-based Product Information Management (PIM) standard. 

    "The SDL translation management software will allow us to optimize, automate and secure the current processes. This should help minimize
the chance of errors and maximize our efficiency when having to manage our multiple language vendors," said Raun Kupiec, Director of
Regulatory Affairs Process Management at Genzyme Europe. "Comparison of versions and quality control is a very challenging task when dealing
simultaneously with 23 languages on tight timelines. A single label change can take up to 100 hours of review. The SDL Global Information
Management software should significantly reduce this burden," adds Kupiec.

    "Genzyme is one of the industry leaders when it comes to the adoption of PIM, the new XML-based standard of the EMEA, and we are
delighted that they have selected an SDL Global Information Management solution as a key element of their multilingual labeling platform,"
said Patrick Baudouin, Vice-President of Life Sciences Solutions at SDL. "Genzyme clearly saw that even if they use external translation
vendors, they will secure as many benefits from the implementation of the SDL solution as companies translating in-house."

    For more information on how SDL is applying Global Information Management best practices to clinical, regulatory (including PIM) and the
commercialization processes please visit www.sdl.com/pim  


    About Genzyme
    One of the world's leading biotechnology companies, Genzyme is dedicated to making a major, positive impact on the lives of people with
serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in
locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the
highest honor awarded by the President of the United States for technological innovation. 

    With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and
apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders,
kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a
substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical
need.


    About SDL
    SDL is the leader in Global Information Management (GIM) solutions that empower organisations to accelerate the delivery of high-quality
multilingual content to global markets. Its enterprise software and services integrate with existing business systems to manage the delivery
of global information from authoring to publication and throughout the distributed translation supply chain. 

    Global industry leaders rely on SDL to provide enterprise software or hosted services for their GIM processes, including ABN-Amro, Best
Western, Bosch, Canon, Chrysler, CNH, Hewlett-Packard, Microsoft, Philips, SAP, Sony, SUN Microsystems and Virgin Atlantic. 

    SDL has implemented more than 480 enterprise GIM solutions, has deployed over 150,000 software licenses across the GIM ecosystem and
provides access to on-demand translation portals for 10 million customers per month. Over 1,000 service professionals deliver consulting,
implementation and language services through its global infrastructure of more than 50 offices in 30 countries. For more information, visit
www.sdl.com 

    All trademarks are the property of their respective owners.


    For more information on SDL, please contact:

    Paul Hampton at SDL
    Tel: +44 (0)1628 416331
    Email: phampton@sdl.com

    Becky Kiely / Sarah Martinez at Octopus Communications
    Tel: +44 (0)845 3700655
    Fax: +44 (0)845 3700654
    Email: sdl@octopuscomms.net  
    Website: www.octopuscomms.net


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
NRAFSFFIASASEDS

Sdl (LSE:SDL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Sdl (LSE:SDL)
Historical Stock Chart
From Jul 2023 to Jul 2024